Chase Pharmaceuticals

Ex-Allergan prez Ingram forges $1B deal to sell Alzheimer’s biotech to Brent Saunders and the new crew at Allergan
Endpoints
Tue, 11/22/16 - 09:55 pm
Allergan
Brent Saunders
Doug Ingram
Alzheimer's disease
Chase Pharmaceuticals